Discover if this is a suitable investor for your startup. If they are we'll make a warm introduction for free. Otherwise, we'll connect you with matching investors.
6 Dimensions Capital is a venture capital firm established in 2017 through the merger of WuXi Healthcare Ventures and Frontline BioVentures. Headquartered in Shanghai, China, the firm has expanded its presence with offices in Boston, Hong Kong, Suzhou, and Palo Alto. The firm focuses on early-stage and growth-stage investments in innovative life science companies, particularly in biotechnology and pharmaceuticals.
With over $1.5 billion in assets under management, 6 Dimensions Capital has positioned itself as a significant player in the life sciences sector. The firm leverages its extensive network and expertise to support portfolio companies in achieving their growth potential. Notable milestones include the successful financing of companies like Curon Biopharmaceutical and Lyvgen Biopharma, showcasing their active role in the market.
6 Dimensions Capital primarily invests in the life sciences sector, targeting innovative healthcare solutions in biotechnology and pharmaceuticals. The firm focuses on both early-stage and growth-stage companies, emphasizing a strong China-US cross-border investment strategy. This approach allows them to leverage the ecosystem of WuXi AppTec, providing unique support to portfolio companies.
The firm seeks to invest in the next wave of global growth opportunities, particularly in biologics, medical devices, in vitro diagnostics (IVD), and healthcare IT. Their check sizes range from seed to growth equity, enabling them to support companies at various stages of development. 6 Dimensions Capital looks for founders who demonstrate a strong vision and the ability to navigate the complexities of the healthcare market.
6 Dimensions Capital has built a diverse portfolio of innovative companies in the life sciences sector. Notable portfolio companies include:
Additionally, the firm has achieved notable exits, including the acquisition of Viela Bio by Horizon Therapeutics for approximately $3.05 billion in 2021.
Leon Chen - CEO & Founding Partner; previously Managing Partner at Frontline BioVentures, he leads the day-to-day operations of the firm.
Erdong Hua - Partner; brings extensive experience in the life sciences sector and is involved in sourcing and managing investments.
Rebecca Zhu - Partner; focuses on investment strategy and portfolio management, leveraging her background in healthcare.
Qin Xie (PhD) - Partner; specializes in biotechnology investments and has a strong academic background in the field.
Colin Wang (PhD) - Partner; brings expertise in drug development and has a history of successful investments in biotech.
Hannes Smárason - Senior Managing Director; oversees strategic initiatives and partnerships within the firm.
Wei Zhao (PhD) - Executive Director; focuses on operational support for portfolio companies and investment analysis.
Jianwei Yuan - Vice President; involved in deal sourcing and due diligence processes.
Jie Zhang (PhD) - Vice President; specializes in healthcare investments and market analysis.
Christina Chung - Chief Financial Officer; manages financial operations and reporting for the firm.
Jin Wang - VP Finance; oversees financial planning and analysis.
Richard Li - Legal Director; handles legal matters and compliance for the firm.
To pitch 6 Dimensions Capital, founders should send an email to ceo.office@6dimensionscapital.com. It is important to include a comprehensive business plan, financial projections, and details about the team. The firm prefers pitches that clearly outline the growth potential and market strategy.
Response times may vary, but founders can expect to hear back within a few weeks. Warm introductions are beneficial but not mandatory.
In recent months, 6 Dimensions Capital has been actively involved in financing notable portfolio companies. They completed a $150 million first round of financing for Curon Biopharmaceutical and led a $30 million Series B funding round for Lyvgen Biopharma.
Additionally, the firm has been recognized for its successful exit with Viela Bio, which was acquired by Horizon Therapeutics for approximately $3.05 billion in 2021. This exit highlights the firm's ability to identify and support high-potential companies in the life sciences sector.
What are 6 Dimensions Capital's investment criteria?
The firm focuses on early-stage and growth-stage investments in the life sciences sector, particularly in biotechnology and pharmaceuticals. They seek innovative healthcare solutions and prioritize companies with a strong China-US cross-border strategy.
How can I pitch to 6 Dimensions Capital?
Founders can reach out via email at ceo.office@6dimensionscapital.com. It is advisable to include a detailed business plan and a clear outline of the company's growth potential.
What makes 6 Dimensions Capital different from other VCs?
The firm leverages its connection with WuXi AppTec, providing unique resources and support to portfolio companies. This relationship enhances their ability to navigate the complexities of the healthcare market.
What is the geographic focus of 6 Dimensions Capital?
6 Dimensions Capital has a global investment strategy, with a particular emphasis on North America, Europe, and Asia, especially China and the United States.
What is the typical check size for investments?
The firm invests across a range from seed to growth equity, allowing flexibility in supporting companies at various stages of development.
What kind of post-investment involvement can founders expect?
6 Dimensions Capital provides strategic guidance and access to resources within the WuXi AppTec ecosystem, enhancing the growth potential of portfolio companies.
All trademarks, logos and brand names are the property of their respective owners. All company, product and service names used in this website are for identification purposes only. Use of these names, trademarks, and brands does not imply endorsement.